Search results
Results from the WOW.Com Content Network
In July 2016, the US Food and Drug Administration (FDA) approved abobotulinumtoxinA (Dysport) for injection for the treatment of lower-limb spasticity in pediatric patients two years of age and older. [53] [54] AbobotulinumtoxinA is the first and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity. [55]
The FDA just approved a unique botulinum toxin A (BoTX-A) called DAXXIFY™ that lasted an average of six months in research subjects. I performed the research trials that led to its FDA approval ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC3+) biliary tract cancer as detected by an FDA approved test [2] Zenocutuzumab: Treatment of adults with advanced, unresectable or metastatic non-small cell lung cancer harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior ...
I tried Daxxify, the new Botox alternative for smoothing fine lines that supposedly lasts longer than the competition. Here's what dermatologists had to say:
The ability to use 'Real World Evidence' (RWE), i.e. post-market evidence of safety and effectiveness, is particularly useful in the context of orphan diseases, where recruiting a sufficiently large cohort for pre-marketing clinical trials may not be feasible. [5] RWE may include data from patient registries, clinical records and case studies. [6]
An earlier petition by Public Citizen in 2008 based on an analysis of 180 reports led to the FDA adding the current black box warning about the risk of Botox's effect spreading to other areas of ...
Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating). [1] Sofpironium bromide is an anticholinergic agent that is applied to the skin. [1] It was approved for medical use in Japan in 2020, [2] and in the United States in June 2024. [1] [3] [4] [5]